Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality

International Journal of COPD

Volumn 2, Issue 1, 2007, Pages 11-18

  Salpeter, Shelley R ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Adrenergic beta agonists; Bronchodilator; Cholinergic antagonists; Chronic obstructive pulmonary disease; Clinical outcomes; COPD; Mortality; Systematic review

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; IPRATROPIUM BROMIDE PLUS SALMETEROL; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG FATALITY; DRUG USE; HOSPITALIZATION; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 34250315383     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: 10.2147/copd.2007.2.1.11     Document Type: Review

References (65)

1. Aaron SD, Vandemheen KL, Hebert P, et al. 2003. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med, 348:2618-25.
2. Alsaeedi A, Sin DD, McAlister FA. 2002. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med, 113:59-65.
3. Anthonisen NR, Connett JE, Enright PL, et al. 2002. Hospitalizations and mortality in the Lung Health Study. Am J Crit Care Med, 166:333-9.
4. Ashutosh K, Lang H. 1984. Comparison between long-term treatment of chronic bronchitic airway obstruction with ipratropium bromide and metaproterenol. Ann Allergy, 53:401-6.
5. [ATP] American Thoracic Society. 1995. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 152(5 Pt 2):S77-121.
6. Barnes PJ. 2004. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med, 117(Suppl 12A):24S-32S.
7. Barr RG, Bourbeau J, Camargo CA, et al. 2005. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2:CD002876.
8. Boyd G, Morice AH, Pounsford JC, et al. 1997. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J, 10:815-21.
9. Brusasco B, Hodder R, Miravitlles M, et al. 2003. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 58:399-404.
10. Brusasco V, Hodder R, Miravitlles M, et al. 2006. Letter to the editor. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 61:91.
11. Calverley PM, Boonsawat W, Cseke Z, et al. 2003. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 22:912-19.
12. Casaburi R, Briggs DD, Jr., Donohue JF, et al. 2000. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multi-center trial. The US Tiotropium Study Group. Chest, 118:1294-302.
13. Casaburi R, Mahler DA, Jones PW, et al. 2002. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19:217-24.
14. Celli BR, MacNee W. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
15. Combivent Inhalation Solution Study Group. 1997. Routine nebulized ipratropium and albuterol are better than either alone in COPD. The Combivent Inhalation Solution Study Group. Chest, 112:1514-21.
16. Cook D, Guyatt G, Wong E, et al. 2001. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:85-90.
17. Donohue JF, Menjoge S, Kesten S. 2003. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med, 97:1014-20.
18. Fahy JV, Boushey HA. 1995. Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Clin Chest Med, 16:715-33.
19. [FDA] US Food and Drug Administration Advisory Committee. 2005. Serevent, Advair, Foradil withdrawals to be considered by Advisory Committee [online]. 8 August 2005. URL: http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/ Pulmonary-Allergy%20Drugs/071305_betasafety/071305_BroncoP.htm.
20. [FDA] US Food and Drug Administration. 2002. NDA 21-395 Spiriva (Tiotropium bromide) inhalation powder for COPD [online]. Accessed on 10 August 2005. URL: http://www.fda.gov/OHRMS/DOCKETS/ ac/02/briefing/ 3890B1_05_Clinical%20Briefing.doc.
21. Friedman M, Serby CW, Menjoge SS, et al. 1999. Pharmocoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest, 115:635-41.
22. Gan WQ, Man SF, Sin DD. 2005. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med, 5:3.
23. GlaxoSmithKline. 2006. GSK announces positive results of Seretide study in patients with chronic obstructive pulmonary disease (COPD) [online]. Accessed on 18 August 2006. URL: http://www.gsk.com/ ControllerServlet?appld=4&pageld=402&newsid=780.
24. Karpel JP. 1991. Bronchodilator responses to anticholinergic and betaadrenergic agents in acute and stable COPD. Chest, 99:871-6.
25. Lipworth BJ. 1992. Risks versus benefits of inhaled beta 2-agonists in the management of asthma. Drug Saf, 7:54-70.
26. Mahler DA, Wire P, Horstman D, et al. 2002. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 166:1084-91.
27. McCrory DC, Brown CD, Gelfand SE, et al. 2001. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest, 119:1190-209.
28. McCrory DC, Brown CD. 2001. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2:CD002984.
29. Michaud CM, Murray CJ, Bloom BR. 2001. Burden of disease - implications for future research. JAMA, 285:535-9.
30. Nannini L, Cates C J, Lasserson T J, et al. 2004. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3:CD003794.
31. [NCCCC] National Collaborating Centre for Chronic Conditions. 2004. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59(Suppl 1): 1-232.
32. Nelson HS, Weiss ST, Bleecker ER, et al. 2006. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest, 129:15-26.
33. Niewoehner DE. 2002. The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Med, 1:243-8.
34. Niewoehner DE, Rice K, Cote C, et al. 2005. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily, inhaled anticholinergic bronchodilator: a randomized trial. Ann Intem Med, 143:317-26.
35. Oostenbrink JB, Rutten-van Molken MP, Al MJ, et al. 2004. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J, 23:241-9.
36. Pauwels RA, Buist AS, Calverley PM, et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med, 163:1256-76.
37. Ramsey SD. 2000. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest, 117(2 Suppl):33S-7S.
38. Rennard SI, Serby CW, Ghafouri M, et al. 1996. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest, 110:62-70.
39. Rennard SI, Anderson W, Zuwallack R, et al. 2001. Use of a long-acting inhaled beta 2-adrenegic agonist, salmeterol xinafoate, in Patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1087-92.
40. Roche N, Lepage T, Bourcereau J, et al. 2001. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J, 18:903-8.
41. Rossi A, Kristufek P, Levine BE, et al. 2002. Comparison of the efficacy, tolerability, and safety of formoterol dry posder and oral, slow-release theophylline in the treatment of COPD. Chest, 121:1058-69.
42. Rudolf M. 2000. The reality of drug use in COPD: the European perspective. Chest, 117(2 Suppl):29S-32S.
43. Salpeter SR, Buckley NS, Ormiston TM, et al. 2006. Long-acting beta-agonists increase severe asthma exacerbations and asthma-related deaths: meta-analysis of randomized controlled trials. Ann Intern Med, 144:904-12.
44. Salpeter SR, Buckley NS, Salpeter EE. 2006. Meta-analysis: Anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med, 21:1011-19.
45. Salpeter SR, Buckley NS. 2006. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: β-Agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol, 31:219-30.
46. Salpeter SR, Ormiston TM, Salpeter EE. 2004. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest, 125:2309-21.
47. Salpeter SR, Ormiston TM, Salpeter EE. 2004. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med, 140:802-13.
48. Sears MR, Taylor DR, Print CG, et al. 1990. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet, 336:1391-6.
49. Sestini P, Renzoni E, Robinson S, et al. 2002. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 4:CD001495.
50. Sin DD, Lacy P, York E, et al. 2004. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 170:760-5.
51. Sin DD, McAlister FA, Man SF, et al. 2003. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA, 290:2301-12.
52. Sin DD, Wu L, Anderson JA, et al. 2005. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax, 60:992-7.
53. Singh JM, Palda VA, Stanbrook MB, et al. 2002. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med, 162:2527-36.
54. Sullivan SD, Ramsey SD, Lee TA. 2000. The economic burden of COPD. Chest, 117(2 Suppl):5S-9S.
55. Sutherland ER, Allmers H, Ayas NT, et al. 2003. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax, 58:937-41.
56. Szafranski W, Cukier A, Ramirez A, et al. 2003. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 21:74-81.
57. Tashkin DP, Ashutosh K, Bleecker ER, et al. 1986. Comparison of the anticholinergie bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Am J Med, 81(5A):81-90.
58. Tashkin DP, Cooper CB. 2004. The role of long-acting bronchodilators in the management of stable COPD. Chest, 125:249-59.
59. Taylor DR, Sears M, Cockcroft DW. 1996. The beta-agonist controversy. Med Clin N Am, 80:719-48.
60. Taylor J, Kotch A, Rice K, et al. 2001. Ipratropium bromide hydrofluoro-alkane inhalation aerosol is safe and effective in patients with COPD. Chest, 120:1253-61.
61. van Grunsven PM, van Schayck CP, Derenne JP, et al. 1999. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax, 54:7-14.
62. Van Overveld F J, Demkow U, Gorecka D, et al. 2006. Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. J Physiol Pharmacol, 57(Suppl 4): 273-82.
63. van Schayck CP, Graafsma S J, Visch MB, et al. 1990. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol, 86:793-800.
64. Wadbo M, Lofdahl CG, Larsson K, et al. 2002. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J, 20:1138-46.
65. Wood-Baker R, Walters EH, Gibson P. 2001. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2:CD001288.